PDCD1 and melanoma: Since anti‐PD‐1 Abs are significantly more effective and have a lower incidence of serious irAEs than ipilimumab,31, 32, 33 anti‐PD‐1 Abs are now the mainstay of advanced melanoma treatment in guidelines.38, 39